Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00586963 · ClinicalTrials.gov registry record
Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 65
- Enrollment target
NCT00586963: Completed study, sponsored by Mayo Clinic.
NCT00586963 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00586963 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 65 participants
- Enrollment target
Study Summary
This study is being done to for two reasons: * To learn about the effects (good and bad) esomeprazole (an FDA approved drug for reflux esophagitis) has on your esophagus when taken correctly. * To learn about the quality of life changes (good and bad) you may experience with this medication.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-12 |
What the finished NCT00586963 record still lists
NCT00586963 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 65 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00586963 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00586963 about?
NCT00586963 is a clinical study titled "Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis". This study is being done to for two reasons: * To learn about the effects (good and bad) esomeprazole (an FDA approved drug for reflux esophagitis) has on your esophagus when taken correctly. * To learn about the quality of life changes (good and bad) you may experience with this medication.
What is the current status of trial NCT00586963?
This trial is currently completed. The enrollment target is 65 participants. The study started on 2008-01. Estimated completion is 2008-12.
Who is sponsoring clinical trial NCT00586963?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia